Unlock instant, AI-driven research and patent intelligence for your innovation.

Modeling method for glomerulus phyllodes nephropathy

A technology for glomerulus and kidney disease, which can be applied in pharmaceutical formulations, urinary system diseases, organic active ingredients, etc., and can solve problems such as no effective drug treatment

Inactive Publication Date: 2020-07-17
长春市儿童医院
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The pathogenesis of renal failure is not yet clear, so there is no effective drug treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Modeling method for glomerulus phyllodes nephropathy
  • Modeling method for glomerulus phyllodes nephropathy
  • Modeling method for glomerulus phyllodes nephropathy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Example 1 Adriamycin combined with cefotaxime to establish a chronic renal failure model in rats

[0024] 1. Selection and grouping of animals

[0025] Rats were selected because most species of rats are very sensitive to doxorubicin kidney damage; the effective dose of doxorubicin for male Wistar rats ranges from 1.5 to 7.5 mg / kg. BALB / c mice need 9.8-10.4 mg / kg, male BALB / c SCID mice only need 5.3 mg / kg. C57BL / c mice are highly resistant to doxorubicin-induced kidney damage, but high doses can induce kidney damage. It is relatively difficult to raise pigs and dogs.

[0026] Grouping: A: normal control group; B: doxorubicin 6.5mg / kg dose group; C: cefotaxime 60mg / kg dose group; D: doxorubicin 6.5mg / kg + cefotaxime 30mg / kg dose group; E: Adriamycin 6.5mg / kg + Cefotaxime 50mg / kg dose group; F: Adriamycin 6.5mg / kg + Cefotaxime 70mg / kg dose group; 6 groups in total, 3 rats in each group, 18 in total Only.

[0027] 2. Drug selection

[0028] Doxorubicin is an anthracy...

Embodiment 2

[0032] Example 2 Detection of urine protein content

[0033] Urine collection: Rats were kept in metabolic cages, water and feed were provided normally, and the 24h urine of each rat was collected and calculated on the 3rd day, 7th day and second week after intramuscular injection, and the collected urine For biochemical assays; grouped into:

[0034] 1) Normal control group: A3, A7, A14

[0035] 2) Adriamycin 6.5mg / kg group: B3, B7, B14

[0036] 3) Cefotaxime 60mg / kg group: C3, C7, C14

[0037] 4) Doxorubicin 6.5mg / kg + cefotaxime 30mg / kg group: D3, D7, D14

[0038] 5) Doxorubicin 6.5mg / kg + cefotaxime 50mg / kg groups: E3, E7, E14

[0039] 6) Doxorubicin 6.5mg / kg + cefotaxime 70mg / kg groups: F3, F7, F14

[0040] 3, 7, and 14 respectively represent the time points of 3 days, 7 days, and 14 days; the results can be seen (Table 1), compared with the normal control group, the urine protein content of the doxorubicin 6.5mg / kg group and the cefotaxime 60mg / kg group The urine p...

Embodiment 3

[0042] Example 3 Serum index detection

[0043] 1. Grouping of rats

[0044] 1) Normal control group: A14, A28

[0045] 2) Adriamycin 6.5mg / kg group: B14, B28

[0046] 3) Cefotaxime 60mg / kg group: C14, C28

[0047] 4) Doxorubicin 6.5mg / kg + cefotaxime 30mg / kg group: D14, D28

[0048] 5) Doxorubicin 6.5mg / kg + cefotaxime 50mg / kg group: E14, E28

[0049] 6) Doxorubicin 6.5mg / kg+ cefotaxime 70mg / kg group: F14, F28;

[0050] 14 and 28 represent time points of 14 days and 28 days respectively;

[0051] 2. Serum creatinine detection

[0052] Under alkaline conditions, creatinine (Cr) in serum reacts with picric acid to form an orange-red complex of picric acid and creatinine. Detect the change of absorbance at 505nm wavelength to know the concentration of creatinine in the measured serum; use creatinine (CR) assay kit (Nanjing Jiancheng); take 0.2ml of serum and add 2ml of tungstic acid protein assay reagent, mix well, 3500 rpm , centrifuge for 10 minutes, take the supernata...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a modeling method for glomerulus phyllodes nephropathy. The method comprises the following steps: intravenously injecting 6.5 mg / kg adriamycin into male Wistar rats on a firstday, injecting30-70 mg / kg cefaloridine every day, and performing injection for three days continuously, wherein in the obtained male Wistar rat nephropathy model, the glomeruli appears lobulated. Themethod provides a novel animal nephropathy model for the study of the pathophysiological mechanism, molecular cytology, and molecular biology of the nephropathy, and provides a basis for the earlier prevention and treatment of clinical patients.

Description

technical field [0001] The invention belongs to the technical field of animal model modeling, and in particular relates to a method for modeling glomerular lobular nephropathy. Background technique [0002] my country is a big country with kidney disease (kidney disease), and the incidence of uremia is 100-130 people / 1 million people, and it is increasing year by year. According to the speed of disease progression, renal failure can be divided into two types: acute renal failure (ARF) and chronic renal failure (CRF). The pathogenesis of renal failure is not yet clear, so there is no effective drug treatment. To study the pathogenesis of renal failure and develop safe and effective drugs has always been an urgent problem in clinical practice. The preclinical research of drugs mainly occurs in the form of animal experiments of the tested drugs, that is, the establishment of animal models, and then the pathogenesis or intervention (pharmaceutical) experimental research. Over...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/704A61K31/546A61P13/12
CPCA61K31/704A61K31/546A61P13/12A61K2300/00
Inventor 姜洪波孙利伟田玉玲杜娟刘宇奇马英伟贺岩赵艳玲张亮
Owner 长春市儿童医院